Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05285826
PHASE3

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be stratified by age and sexual orientation, and will have two stages. The primary hypothesis of Stage I is: 9vHPV vaccine reduces the combined incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related external genital and intra-anal 12-month persistent infection (PI) compared with placebo in males 20 to 45 years of age who are seronegative at Day 1 and polymerase chain reaction (PCR) negative from Day 1 through one month post-Dose 3 to the relevant HPV type. The primary hypothesis of Stages I and II combined is: 9vHPV vaccine reduces the combined incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related genital warts, penile/perianal/perineal intraepithelial neoplasia (PIN), or penile/perianal/perineal cancer compared with placebo in males 20 to 45 years of age who are seronegative at Day 1 and PCR negative from Day 1 through one month post-Dose 3 to the relevant HPV type.

Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy, Immunogenicity, and Safety of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine, in Chinese Males 20 to 45 Years of Age

Key Details

Gender

MALE

Age Range

20 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

8100

Start Date

2022-02-18

Completion Date

2029-05-25

Last Updated

2024-12-16

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

9vHPV Vaccine

9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine administered as a 0.5-mL IM injection

OTHER

Placebo

Sterile saline solution administered as a 0.5 mL IM injection

Locations (34)

Beijing Youan Hospital ( Site 0001)

Beijing, Beijing Municipality, China

The Second Affiliated Hospital Chongqing Medical University ( Site 0052)

Chongqing, Chongqing Municipality, China

Chongqing Public Health Medical Center ( Site 0003)

Chongqing, Chongqing Municipality, China

The First Hospital of Lanzhou University ( Site 0034)

Lanzhou, Gansu, China

Southern Medical University Nanfang Hospital-Center for Drug Clinical Research ( Site 0031)

Guangzhou, Guangdong, China

The University of Hong Kong - Shenzhen Hospital ( Site 0049)

Shenzhen, Guangdong, China

Center for Disease Control and Prevention of Rong An ( Site 0046)

Liuchow, Guangxi, China

Liucheng County Centers for Disease Control and Prevention ( Site 0045)

Liuchow, Guangxi, China

Wuhan Union Hospital ( Site 0032)

Wuhan, Hubei, China

Hunan Provincial Center for Disease Control and Prevention ( Site 0040)

Changsha, Hunan, China

The Third Xiangya Hospital of Central South University ( Site 0033)

Changsha, Hunan, China

Loudi Disease Prevention and Control Center Zhiyebing Prevention And Treatment Hospital ( Site 0015)

Louxing District, Hunan, China

Xiangtan Disease Prevention and Control Center ( Site 0030)

Xiangtan, Hunan, China

Xiangxiang Disease Prevention and Control Center ( Site 0016)

Xiangxiang, Hunan, China

Qiyang Center for Disease Control and Prevention ( Site 0014)

Yongzhou, Hunan, China

The Second Hospital of Nanjing (Tangshan Branch) ( Site 0028)

Nanjing, Jiangsu, China

The first affiliated hospital of China medical university ( Site 0041)

Shenyang, Liaoning, China

Liaoning University of Traditional Chinese Medicine Affiliated Hospital ( Site 0048)

Shenyang, Liaoning, China

Yuanqu Center for Disease Control and Prevention ( Site 0019)

Yuncheng, Shanxi, China

Yanhu Center for Disease Control and Prevention of Yuncheng ( Site 0018)

Yuncheng, Shanxi, China

Yongji Center for Disease Control and Prevention ( Site 0026)

Yuncheng, Shanxi, China

Ruicheng Center for Disease Control and Prevention ( Site 0025)

Yuncheng, Shanxi, China

Dazhu Disease Prevention and Control Center ( Site 0010)

Dazhou, Sichuan, China

Yuechi Disease Prevention and Control Center ( Site 0009)

Guang’an, Sichuan, China

Mianyang Center for Disease Control and Prevention ( Site 0007)

Mianyang, Sichuan, China

Santai County Center for Disease Control and Prevention ( Site 0008)

Mianyang, Sichuan, China

Neijiang Center for Disease Control and Prevention ( Site 0011)

Neijiang, Sichuan, China

Tianjin Second People's Hospital ( Site 0004)

Tianjin, Tianjin Municipality, China

Tianjin People' s Hospital ( Site 0038)

Tianjin, Tianjin Municipality, China

Binchuan County Center for Disease Control and Prevention ( Site 0022)

Dali, Yunnan, China

Xiangyun County Center for Disease Control and Prevention ( Site 0021)

Dali, Yunnan, China

First Affiliated Hospital of Kunming Medical University ( Site 0051)

Kunming, Yunnan, China

Yunnan Provincial Infectious Disease Hospital ( Site 0042)

Kunming, Yunnan, China

Zhejiang University School of Medicine - Affiliated Wenzhou Traditional Chinese Medicine Hospital (W

Wenzhou, Zhejiang, China